All Stories

  1. Glucocorticoid-induced osteoporosis: an overview with focus on its prevention and management
  2. Similarities and Differences in the Management of Patients with Osteoporotic Vertebral Fractures and Those with Rebound-Associated Vertebral Fractures Following Discontinuation of Denosumab
  3. Lipid Profile after Pharmacologic Discontinuation and Restoration of Menstruation in Women with Endometriosis: A 12-Month Observational Prospective Study
  4. Association of activins, follistatins and inhibins with incident hip fracture in women with postmenopausal osteoporosis: a proof of concept, case–control study
  5. Irisin and Bone in Sickness and in Health: A Narrative Review of the Literature
  6. Adult Langerhans Cell Histiocytosis and the Skeleton
  7. Irisin in nonalcoholic fatty liver disease: need for an updated meta-analysis
  8. Beyond glycemic control: New guidance on cardio-renal protection
  9. Bazedoxifene for the treatment of osteoporosis
  10. Asymptomatic and normocalcemic hyperparathyroidism, the silent attack: a combo-endocrinology overview
  11. Bone metabolism in Langerhans cell histiocytosis
  12. Bone disease in primary hyperparathyroidism
  13. Tips, Tricks, and Advantages of 27-G Vitrectomy
  14. Bisphosphonates or denosumab discontinuation and risk of fractures
  15. Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatment
  16. Circulating microRNAs in postmenopausal women with osteoporosis and vertebral fractures
  17. Circulating microRNAs in postmenopausal women with osteoporosis and vertebral fractures
  18. Multiple clinical vertebral fractures following denosumab discontinuation
  19. Periostin on the road to nonalcoholic fatty liver disease
  20. Novel therapies for osteoporosis
  21. Rationale for the Application of RANKL Inhibition in the Treatment of Langerhans Cell Histiocytosis
  22. Circulating semaphorin-4D and plexin-B1 levels in postmenopausal women with low bone mass: the 3-month effect of zoledronic acid, denosumab or teriparatide treatment
  23. The Effect of Leptin Replacement on Parathyroid Hormone, RANKL-Osteoprotegerin Axis, and Wnt Inhibitors in Young Women With Hypothalamic Amenorrhea
  24. Circulating periostin levels in patients with AS: association with clinical and radiographic variables, inflammatory markers and molecules involved in bone formation
  25. Investigational parathyroid hormone receptor analogs for the treatment of osteoporosis
  26. THU0080 Association of Serum Periostin Levels with Disease Activity and Radiographic Damage, as Well as Serum Bone Formation Markers, in Patients with Ankylosing Spondylitis
  27. Circulating irisin is associated with osteoporotic fractures in postmenopausal women with low bone mass but is not affected by either teriparatide or denosumab treatment for 3 months
  28. Denosumab Treatment for Juvenile Paget's Disease: Results From Two Adult Patients With Osteoprotegerin Deficiency (“Balkan” Mutation in theTNFRSF11BGene)
  29. Irisin in patients with nonalcoholic fatty liver disease
  30. Coexistence of Graves’ disease, papillary thyroid carcinoma and unilateral benign struma ovarii: Case report and review of the literature
  31. Circulating Periostin Levels do not Differ Between Postmenopausal Women with Normal and Low Bone Mass and are not Affected by Zoledronic Acid Treatment
  32. Comparative Effect of Zoledronic Acid Versus Denosumab on Serum Sclerostin and Dickkopf-1 Levels of Naive Postmenopausal Women With Low Bone Mass: A Randomized, Head-to-Head Clinical Trial
  33. Efficacy of Anti-TNF Agents as Adjunctive Therapy for Knee Synovitis Refractory to Disease-Modifying Antirheumatic Drugs in Patients with Peripheral Spondyloarthritis
  34. Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosis
  35. Disease-modifying anti-rheumatic drugs for refractory severe knee synovitis in patients with peripheral spondyloarthritis: efficacy and predictors of response
  36. Serum vaspin levels in women with and without gestational diabetes mellitus during pregnancy and postpartum
  37. Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosis
  38. Serum sclerostin levels following treatment with parathyroid hormone
  39. Serum vaspin levels in women with and without gestational diabetes mellitus during pregnancy and postpartum
  40. Central skeletal sarcoidosis: a case report with sustained remission only on methotrexate, and a literature review on the imaging approach, treatment, and assessment of disease activity
  41. The role of cytokines and adipocytokines in zoledronate‐induced acute phase reaction in postmenopausal women with low bone mass
  42. Leflunomide addition in patients with articular manifestations of psoriatic arthritis resistant to methotrexate
  43. Circulating activin-A is elevated in postmenopausal women with low bone mass: the three-month effect of zoledronic acid treatment
  44. Papillary thyroid microcarcinoma presenting as lymph node metastasis – a diagnostic challenge: case report and systematic review of literature
  45. Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab
  46. Long-term effects of thyroid fine-needle biopsy on the thyroid-related biochemical parameters
  47. High Circulating Sclerostin is Present in Patients with Thalassemia-associated Osteoporosis and Correlates with Bone Mineral Density
  48. Acute phase response following intravenous zoledronate in postmenopausal women with low bone mass
  49. Acute transient thyroid swelling following needle biopsy: An update
  50. Serum Osteoprotegerin, RANKL, and Dkk-1 Levels in Adults with Langerhans Cell Histiocytosis
  51. Selenomethionine treatment in patients with autoimmune thyroiditis: a prospective, quasi-randomised trial
  52. Is Serum IL-17A a Useful Systemic Biomarker in Patients With Langerhans Cell Histiocytosis?
  53. Role of wingless tail signaling pathway in osteoporosis
  54. Clinical Efficacy and Safety of Denosumab in Postmenopausal Women with Low Bone Mineral Density and Osteoporosis: A Meta-Analysis
  55. Apelin levels in normal pregnancy
  56. Paget’s Disease of Bone and Calcium Homeostasis: Focus on Bisphosphonate Treatment
  57. Targeting the osteoblast: approved and experimental anabolic agents for the treatment of osteoporosis
  58. Denosumab and bisphosphonates: Rivals or potential “partners”? A “hybrid” molecule hypothesis
  59. Reduced bone mineral density in adult patients with Langerhans cell histiocytosis
  60. Authors' Response to Dr. Lutz Schomburg
  61. Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women — The six-month effect of risedronate and teriparatide
  62. Oxidized low-density lipoprotein and adiponectin levels in pregnancy
  63. Serum vaspin levels in normal pregnancy in comparison with non-pregnant women
  64. No Effect of Rosuvastatin in the Zoledronate-Induced Acute-Phase Response
  65. Distinctive growth pattern in a patient with a delayed diagnosis of Langerhans’ cell histiocytosis
  66. Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women—the six-month effect of risedronate and teriparatide
  67. Selenium Supplementation in the Treatment of Hashimoto's Thyroiditis: A Systematic Review and a Meta-analysis
  68. Infectious thyroiditis as a complication of fine-needle biopsy: a systematic review
  69. Primary hyperparathyroidism and incidental multifocal metastatic papillary thyroid carcinoma in a man
  70. A case report of subacute thyroiditis during pregnancy: difficulties in differential diagnosis and changes in cytokine levels
  71. Profound hypocalcemia following effective response to zoledronic acid treatment in a patient with juvenile Paget’s disease
  72. The effect of teriparatide on serum Dickkopf‐1 levels in postmenopausal women with established osteoporosis
  73. Zoledronic acid-induced transient hepatotoxicity in a patient effectively treated for Paget’s disease of bone
  74. Alterations in Serum Thyroid–Related Constituents After Thyroid Fine-Needle Biopsy: A Systematic Review
  75. Erratum to: Increased risk of serious infections in women with osteopenia or osteoporosis treated with denosumab
  76. Increased risk of serious infections in women with osteopenia or osteoporosis treated with denosumab
  77. Serum homocysteine, folate and vitamin B12 in patients with Paget’s disease of bone: the effect of zoledronic acid
  78. Paget’s disease of bone: emphasis on treatment with zoledronic acid
  79. The Effect of Zoledronic Acid on Serum Dickkopf-1, Osteoprotegerin, and RANKL in Patients with Paget's Disease of Bone
  80. Transient secondary hyperparathyroidism following intravenous infusion of zoledronic acid
  81. Clinical complications following thyroid fine‐needle biopsy: a systematic review
  82. Normochromic normocytic anemia in a postmenopausal woman with severe osteoporosis treated with intermittent parathyroid hormone
  83. RANKL inhibition for the management of patients with benign metabolic bone disorders
  84. Efficacy and Safety of Denosumab in Postmenopausal Women with Osteopenia or Osteoporosis: A Systematic Review and a Meta-analysis
  85. Serum Dikkopf-1 levels in postmenopausal women with established osteoporosis before and after treatment with teriparatide
  86. The effect of zoledronic acid on serum Dickkopf-1, osteoprotegerin and rankl in patients with paget's disease of bone
  87. Thiazolidinedione use and the risk of fractures
  88. No difference between strontium ranelate (SR) and calcium/vitamin D on bone turnover markers in women with established osteoporosis previously treated with teriparatide: a randomized controlled trial
  89. Effect of Strontium Ranelate on Lumbar Spine Bone Mineral Density in Women with Established Osteoporosis Previously Treated with Teriparatide
  90. Effects of Two Years of Daily Teriparatide Treatment on BMD in Postmenopausal Women With Severe Osteoporosis With and Without Prior Antiresorptive Treatment
  91. Effect of Exogenous Intermittent Recombinant Human PTH 1–34 Administration and Chronic Endogenous Parathyroid Hormone Excess on Glucose Homeostasis and Insulin Sensitivity
  92. Head-to-head comparison of risedronate vs. teriparatide on bone turnover markers in women with postmenopausal osteoporosis: a randomised trial
  93. Serum Osteoprotegerin and RANKL are not Specifically Altered in Women with Postmenopausal Osteoporosis Treated with Teriparatide or Risedronate: A Randomized, Controlled Trial
  94. Acute changes in serum osteoprotegerin and receptor activator for nuclear factor-κB ligand levels in women with established osteoporosis treated with teriparatide
  95. Endogenous Intact PTH is Suppressed during Teriparatide (rhPTH 1-34) Administration in Postmenopausal Women with Established Osteoporosis
  96. Acute and Chronic Effect of Teriparatide on Glucose Metabolism in Women with Established Osteoporosis